Combination of olanzapine and samidorphan will prevent unwanted weight gain in patients.
Regulatory
Actions of government agencies regulating the pharmaceutical industry: approval, rejection, and prohibition of drugs, granting special statuses.
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Zynrelef: New Drug for Postoperative Pain Relief
A proprietary formulation of bupivacaine with meloxicam, developed by Heron Therapeutics, relieves acute pain for 72 hours after surgery.
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Opdivo and Keytruda: First-line Immunotherapy for Gastric Cancer and Esophageal Cancer
Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.